LENVATINIB MESYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2015)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 3J78384F61
Parent Compound: LENVATINIB

Structure
InChI Key HWLFIUUAYLEFCT-UHFFFAOYSA-N
Smile COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O.CS(=O)(=O)O
InChI
InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H23ClN4O7S
Molecular Weight 522.97
AlogP 4.07
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 6.0
Polar Surface Area 115.57
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 30.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Vascular endothelial growth factor receptor inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Thyroid Neoplasms 4 D013964 FDA
Cholangiocarcinoma 2 D018281 ClinicalTrials
Carcinoma, Pancreatic Ductal 2 D021441 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 1 D002289 ClinicalTrials
Melanoma 1 D008545 ClinicalTrials

Related Entries

Scaffolds

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
15.94
General disorders and administration site conditions
12.02
Vascular disorders
9.43
Nervous system disorders
8.51
Investigations
7.93
Respiratory, thoracic and mediastinal disorders
6.8
Metabolism and nutrition disorders
6.64
Musculoskeletal and connective tissue disorders
4.55
Cardiac disorders
4.0
Skin and subcutaneous tissue disorders
3.96
Renal and urinary disorders
3.3
Infections and infestations
3.21
Hepatobiliary disorders
3.09
Psychiatric disorders
2.69
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.35
Injury, poisoning and procedural complications
2.08

Cross References

Resources Reference
ChEBI 85995
ChEMBL CHEMBL2105704
EPA CompTox DTXSID90235081
FDA SRS 3J78384F61
PubChem 11237762
SureChEMBL SCHEMBL865174
CONTENTS